Članovi Akademije

Julius Stevo

Akademske titule:

• profesor doktor znanosti

Članstvo u Akademiji:

• dopisni član – Razred za medicinske znanosti (10.05.2012. – …)

---

Biografija

Stevo Julius, hrvatski liječnik, rođen je 1929. u Kovinu u Srbiji, a sa sedam godina doselio se s obitelji u Zagreb gdje je završio osnovnu i srednju školu. Od svoje 14. godine bio je sudionik Antifašističke borbe. Diplomirao je na Medicinskom fakultetu u Zagrebu 1953., a 1964. doktorirao. Kao specijalist interne medicine i asistent u Internoj klinici Rebro radio do 1964. Tada je otišao na Sveučilište države Michigan u Ann Arbor u SAD, gdje bio voditelj Odsjeka za hipertenziju i nastavnik više od 40 godina. Istraživački interes profesora Juliusa usmjeren je na područje patofiziologije ranih faza arterijske hipertenzije i metaboličkog sindroma. Danas je aktivan professor emeritus interne medicine i fiziologije. Gost je profesor na Medicinskom fakultetu u Zagrebu i Padovi te počasni doktor znanosti Sveučilišta u Göteborgu u Švedskoj. Isto je tako počasni član Australskog, Hrvatskog, Europskog, Finskog, Mađarskog, Meksičkog, Španjolskog, Poljskog i Švedskog društva za hipertenziju.
Dr. Julius autor je više od 400 objavljenih radova u vodećim svjetskim časopisima i poglavlja u knjigama, a o njegovu široku intelektualnom interesu svjedoče dvije knjige memoara: Neither Red Nor Dead i Adventures in Hypertension. Član je uredničkih odbora najuglednijih časopisa iz područja hipertenzije. Primio je Nagradu za životno djelo i priznanje The Corcoran Lectureship Savjeta za istraživanje hipertenzije Američkoga kardiološkog društva, Nagradu William Harvey Američkog društva za hipertenziju (William Harvey Award of the American Society of Hypertension), The Astra Cardiovascular Award Međunarodnog društva za hipertenziju (International society of hypertension – ISH), Distinguished Faculty Award Sveučilišta države Michigan, Nagradu MERIT Državnih instituta za zdravlje (National Institutes of Health – NIH) te počasti Europskoga i Japanskoga društva za hipertenziju. Međunarodno društvo za hipertenziju (ISH) osnovalo je nagradu Stevo Julius Award for Excellence in Hypertension Education za najuglednije nastavnike. Dugogodišnji doprinos profesora Juliusa istraživanju i liječenju arterijske hipertenzije ostavio je trajan i najdublji trag u svjetskoj znanosti, a posebno je zaslužan za razvoj i unaprjeđenje istraživanja i liječenja arterijske hipertenzije u Hrvatskoj. Za dopisnog člana HAZU izabran je 2012.

Stevo Julius – Osobna stranica

---

Bibliografija

1. Julius S, Hranilovic B, Pokrajac N:  Iz problematike hipertireoze.  Medicinar pp. 331-343, 1950.

2. Julius S:  Dijagnostika Neurovegetativne Distonije.  Med Glas, pp. 1-6, 1958.

3. Julius S:  O Nervnoj Regulaciji Krvne Slike.  Neuropsihijatrija pp. 58-67, 1958.

4. Conway J, Zweifler AJ, Julius S:  The place of methyldopa in the treatment of severe hypertension.  JAMA 186:266-268, 1963.

5. McGinn NF, Harburg E, Julius S, McLeod JW:  Psychological correlates of blood pressure.  Psychol Bull 61:209-219, 1964.

6. Julius S, McGinn NF, Harburg E, Hoobler SW:  Comparison of various clinical measurements of blood pressure with the self-determination technique in normotensive college males.  J Chronic Dis 17:391-396, 1964.

7. Julius S, Harburg E, McGinn NF, Keyes J, Hoobler SW:  Relation between casual blood pressure readings in youth and at age 40.  J Chronic Dis 17:397-404, 1964.

8. Harburg E, Julius S, McGinn NF, McLeod J, Hoobler SW:  Personality traits and behavioral patterns associated with systolic blood pressure levels in college males.  J Chronic Dis 17:405-414, 1964.

9. McGinn NF, Harburg E, Julius S:  Blood pressure reactivity and recall of treatment by parents.  J Pers Soc Psychol 1:147-153, 1965.

10. Julius S, Amery A, Whitlock SL, Conway J:  Influence of age on the hemodynamic response to exercise.  Circulation 36:222-230, 1967.

11. Amery A, Julius S, Whitlock LS, Conway J:  Influence of hypertension on the hemodynamic response to exercise.  Circulation, 36:231-237, 1967.

12. Julius S, Stewart BH:  Diagnostic significance of abdominal murmurs.  N Engl J Med 276:1175-1178, 1967.

13. Conway J, Julius S, Amery A:  Effect of blood pressure level on the hemodynamic response to exercise.  Hypertension 16:79-85, 1968.

14. Julius S, Conway J:  Hemodynamic studies in patients with borderline blood pressure elevation.  Circulation 38:282-288, 1968.

15. Ferguson RJ, Faulkner JA, Julius S, Conway J:  Comparison of cardiac output determined by CO2 rebreathing and dye-dilution methods.  J Appl Physiol 25:450-454, 1968.

16. Smet G, Hoobler SW, Sanbar S, Julius S:  Clinical observations on a new antihypertensive drug, 2-(2,6-dichlorphenylamine)-2-imidazoline hydrochloride.  Am Heart J 77:473-478, 1969.

17. Sannerstedt R, Julius S, Conway J:  Hemodynamic response to tilt and beta-adrenergic blockade in young patients with borderline hypertension.  Circulation 42:1057-1064, 1970.

18. Julius S, Pascual A, Reilly K, London R:  Abnormalities of plasma volume in borderline hypertension.  Arch Intern Med 127:116-119, 1971.

19. Julius S, Schork MA:  Borderline hypertension – a critical review.  J Chronic Dis 23:723-754, 1971.

20. Julius S, Pascual A, Sannerstedt R, Mitchell C:  Relationship between cardiac output and peripheral resistance in borderline hypertension.  Circulation 43:382-390, 1971.

21. Julius S, Pascual AV, London R:  Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension.  Circulation 44:413-418, 1971.

22. Julius S, Pascual AV, Abbrecht P, London R:  Effect of beta-adrenergic blockade on plasma volume in human subjects.  Proc Soc Exp Biol Med 140:982-985, 1972.

23. Pascual AV, Julius S:  Short-term effectiveness and hemodynamic actions of guanadrel, a new sympatholytic drug.  Curr Ther Res 14:333-341, 1972.

24. Sannerstedt R, Julius S:  Systemic haemodynamics in borderline arterial hypertension:  Responses to static exercise before and under the influence of propranolol.  Cardiovasc Res 6:398-403, 1972.

25. Hansson L, Julius S, Sannerstedt R:  Latent hypertension.  Sartryck ur Lakartidningen 69:4011-4014, 1972.

26. Hansson L, Hunyor SN, Julius S and Hoobler SW:  Blood pressure crisis following withdrawal of clonidine (Catapres, Catapresan), with special reference to arterial and urinary catecholamine levels, and suggestions for acute management.  Am Heart J 85:605-610, 1973.

27. Hansson L, Pascual A, Julius S:  Comparison of guanadrel and guanethidine.  Clin Pharmacol Ther 14:204-208, 1973.

28. Ellis CN, Julius S:  Role of central blood volume in hyperkinetic borderline hypertension.  Br Heart J 35:450-455, 1973.

29. Ernst CB, Hansson L, Hunyor SN, Julius S:  Stimulering av sinusnerverna med implanterad baropacer vid terapiresistent hypertension.  (Stimulation of the sinus nerves with implanted baropacer in patients with therapy resistant hypertension.)  Lakartidningen 70:1166-1168, 1973.

30. Folkow B, Hallback M, Lundgren Y, Weiss L, Albrecht I, Julius S:  Analysis of design and reactivity of series-coupled vascular sections in spontaneously hypertensive rats (SHR).  Acta Physiol Scand 90:654-656, 1974.

31. Julius S, Ellis CN, Pascual AV, Matice M, Hansson L, Hunyor SN, Sandler LN:  Home blood pressure determination:  value in borderline (“labile”) hypertension.  JAMA 229:663-666, 1974.

32. Hansson L, Zweifler AJ, Julius S, Hunyor SN:  Hemodynamic effects of acute and prolonged b-adrenergic blockade in essential hypertension.  Acta Med Scand 196:27-34, 1974.

33. Hansson L, Zweifler AJ, Julius S, Ellis CN:  Propranolol therapy in essential hypertension.  Observations on predictability of therapeutic response.  Int J Clin Pharmacol 10:79-89, 1974.

34. Julius S, Hansson L:  Hemodynamics of prehypertension and hypertension.  Verh Dtsch Ges Inn Med 80:49-58, 1974.

35. Julius S, Esler MD, Randall OS, Ellis CN:  Neurogenic maintenance of peripheral resistance in borderline hypertension.  Acta Physiol Lat Am 24:425-431, 1974.

36. Hypertension-Stroke Cooperative Study Group.  Effect of antihypertensive treatment on stroke recurrence.  JAMA 229:409-418, 1974.

37. Julius S, Esler MD, Randall OS:  Role of the autonomic nervous system in mild human hypertension.  Clin Sci Mol Med 48:243s-252s, 1975.

38. Esler MD, Julius S, Randall OS, Ellis CN, Kashima T:  Relation of renin status to neurogenic vascular resistance in borderline hypertension.  Am J Cardiol 36:708-715, 1975.

39. Julius S, Randall OS, Esler MD, Kashima T, Ellis CN, Bennett J:  Altered cardiac responsiveness and regulation in the normal cardiac output type of borderline hypertension.  Circ Res 36-37 (Suppl. I):I-199-I-207, 1975.

40. Albrecht I, Hallback M, Julius S, Lundgren Y, Stage L, Weiss L, Folkow B:  Arterial pressure, cardiac output and systemic resistance before and after pithing in normotensive and spontaneously hypertensive rats.  Acta Physiol Scand 94:378-385, 1975.

41. Julius S, Esler M:  Autonomic nervous cardiovascular regulation in borderline hypertension.  Am J Cardiol 36:685-696, 1975.

42. Esler M, Zweifler A, Randall O, Julius S, Bennett J, Rydelek P:  Suppression of sympathetic nervous function in low-renin essential hypertension.  Lancet 2:115-118, 1976.

43. Julius S:  Borderline hypertension:  definitions and treatment.  Cardiovasc Med 1:77-87, 1976.

44. Julius S:  Abnormalities of autonomic nervous control in borderline hypertension.  Schweiz Med Wochenschr 106:1698-1705, 1976.

45. Esler M, Julius S, Randall O, DeQuattro V, Zweifler A:  High-renin essential hypertension:  adrenergic cardiovascular correlates.  Clin Sci Mol Med 51:181s-184s, 1976.

46. Julius S, Esler M:  Increased central blood volume:  A possible pathophysiological factor in mild low-renin essential hypertension.  Clin Sci Mol Med 51:207s-210s, 1976.

47. Randall OS, Esler MD, Bulloch GF, Maisel AS, Ellis CN, Zweifler AJ, Julius S:  Relationship of age and blood pressure to baroreflex sensitivity and arterial compliance in man.  Clin Sci Mol Med 51:357s-360s, 1976.

48. Julius S, Esler M, Hansson L, Zweifler AJ: Dissociation of the renin lowering and antihypertensive actions of propranolol.  Advances in Clin Pharmacology 11:33-41, 1976.

49. Esler M, Julius S, Zweifler A, Randall O, Harburg E, Gardiner H, DeQuattro V.  Mild high-renin essential hypertension:  Neurogenic human hypertension?  N Engl J Med 296:405-411, 1977.

50. Julius S:  Borderline hypertension:  an overview.  Med Clin North Am 61:495-511, 1977.

51. Simon G, Kiowski W, Julius S:  Effect of beta adrenoceptor antagonists on baroreceptor reflex sensitivity in hypertension.  Clin Pharmacol Ther 22:293-298, 1977.

52. Julius S, Esler M: Patterns of neurogenic involvement in borderline and essential hypertension.  Progress in Brain Research 47:251-62, 1977.

53. Julius S:  Clinical and physiological significance of borderline hypertension at youth.  Ped Clin North Am 25:35-45, 1978.

54. Simon G, Kiowski W, Julius S:  Antihypertensive and ß-adrenoceptor antagonist action of timolol.  Clin Pharmacol Ther 23:152-157, 1978.

55. Randall O, Esler M, Culp B, Julius S and Zweifler A:  Determinants of baroreflex sensitivity in man.  J Lab Clin Med 91:514-519, 1978.

56. Esler M, Zweifler A, Randall O, Julius S, DeQuattro V:  The determinants of plasma-renin activity in essential hypertension.  Ann Int Med 88:746-752, 1978.

57. Kiowski W, Julius S:  Renin response to stimulation of cardiopulmonary mechanoreceptors in man.  J Clin Invest 62:656-663, 1978.

58. Simon G, Kiowski W, Julius S:  Left ventricular performance during antihypertensive therapy with timolol.  Curr Ther Res 25:626-632, 1979.

59. Simon G, Kiowski W, Julius S:  Effect of systemic autonomic inhibition on the hemodynamic response to antihypertensive therapy with timolol.  Int J Clin Pharmacol Biopharm 17:507-510, 1979

60. Shapiro AP, Benson H, Chobanian AV, Herd JA, Julius S, Kaplan N, Lazarus RS, Ostfeld AM, Syme SL. The role of stress in hypertension.  J Human Stress 5(2):7-26, 1979.

61. Nicholls MG, Kiowski W, Zweifler AJ, Julius S, Schork MA, Greenhouse J:  Plasma norepinephrine variations with dietary sodium intake.  Hypertension 2:29-32, 1980.

62. Julius S, Hansson L, Andren L, Gudbrandsson T, Sivertsson R, Svensson A:  Borderline hypertension (Hypertension Seminars at Ostra Hospital, Goteborg, Sweden).  Acta med Scand 208:481-489, 1980.

63. Zweifler AJ, Julius S, Nicholls MG:  Efficacy of an oral angiotensin converting enzyme inhibitor (captopril) in severe hypertension.  Arch Int Med 141:907-910, 1981.

64. Nicholls MG, Julius S, Zweifler AJ:  Withdrawal of endogenous sympathetic drive lowers blood pressure in primary aldosteronism.  Clin Endocrinol 15:253-258, 1981.

65. Kiowski W, Randall OS, Steffens TG, Julius S:  Reliability of echocardiography in assessing cardiac output.  Klin Wochenschr 59:1115-1120, 1981.

66. Nicholls MG, Espiner EA, Miles KD, Zweifler AJ, Julius S:  Evidence against an interaction of angiotensin II with the sympathetic nervous system in man.  Clin Endocrinol 15:423-430, 1981.

67. Victery W, Vander A, Shulak J, Shoeps P, Julius S:  Lead hypertension and the renin-angiotensin system in rats.  J Lab Clin Med 99:354-362, 1982.

68. Zweifler A, Julius S:  Increased platelet catecholamine content in pheochromocytoma.  A diagnostic test in patients with elevated plasma catecholamines.  N Engl J Med 306:890-894, 1982.

69. Cottier C, Julius S, Gajendragadkar SV, Schork MA:  Usefulness of home BP determination in treating borderline hypertension.  JAMA 248:555-558, 1982.

70. Julius S, Sanchez R, Malayan S, Hamlin M, Elkins M, Brant D, Bohr DF:  Sustained blood pressure elevation to lower body compression in pigs and dogs.  Hypertension 4:782-788, 1982.

71. Cottier C, Julius S:  Use of clonidine and propranolol as monotherapy in borderline hypertension.  Chest 83:422-425, 1983.

72. Ibsen H, Egan B, Osterziel K, Julius S:  Reflex hemodynamic adjustments and baroreflex sensitivity during converting enzyme inhibition with MK-421 in normal man.  Hypertension 5 (Suppl. I): I-184-I-191, 1983.

73. Egan B, Julius S. Borderline hypertension.  Primary Care; Clinics in Office Practice 10(1):99-113, 1983.

74. Julius S, Cottier C, Egan B, Ibsen H, Kiowski W:  Cardiopulmonary mechanoreceptors and renin release in humans.  Federation Proc 42:2703-2708, 1983.

75. Egan BM, Julius S, Cottier C, Osterziel KJ, Ibsen H:  The role of cardiovascular receptors on the neural regulation of renin release in normal man.  Hypertension 5:779-786, 1983.

76. Ibsen H, Egan B, Julius S:  Baroreflex sensitivity during converting enzyme inhibition with Enalapril (MK-421) in normal man.  J Hypertension 1 (suppl 2):222-224, 1983.

77. Ferguson JJ, Julius S, Randall OS:  Stroke volume-pulse pressure relationships in borderline hypertension:  A possible indicator of decreased arterial compliance.  J Hypertension 2 (suppl. 3):397-399, 1984.

78. Weder AB, Torretti BA, Julius S:  Racial differences in erythrocyte cation transport.  Hypertension 6:115-123, 1984.

79. Colfer HT, Cottier C, Sanchez R, Julius S:  Role of cardiac factors in the initial hypotensive action by beta-adrenoreceptor blocking agents.  Hypertension 6:145-151, 1984.

80. Ibsen H, Julius S:  Pharmacologic tools for assessment of adrenergic nerve activity in human hypertension.  Federation Proc 43:67-71, 1984.

81. Cottier C, Shapiro K, Julius S:  Treatment of mild hypertension with progressive muscle relaxation:  Predictive value of indices of sympathetic tone.  Arch Int Med 144:1954-1958, 1984.

82. Osterziel KJ, Julius S, Brant D:  Blood pressure elevation during hindquarter compression in dogs is neurogenic.  J Hypertension 4:411-417, 1984.

83. Egan B, Grekin R, Ibsen H, Osterziel K, Julius S:  The role of cardiopulmonary mechanoreceptors in the ADH release in normal man.  Hypertension 6:832-836, 1984.

84. Weder AB, Julius S:  Behavior, blood pressure variability and hypertension.  Psychosom Med 47:406-414, 1985.

85. Egan B, Neubig R, Schneider R, Julius S:  Methods for measuring vascular and nonvascular alpha-receptor sensitivity in humans.  J Cardiovasc Pharmacol 7(Suppl 6):S153-S158, 1985.

86. Egan B, Julius S:  Vascular hypertrophy in borderline hypertension:  Relationship to blood pressure and sympathetic drive.  Clin Exp Hypertension – Theory and Practice A7:243-255, 1985.

87. Egan B, Neubig R, Julius S:  Pharmacologic reduction of sympathetic drive increases platelet alpha2-receptor number.  Clin Pharm Therap 38:519-524, 1985.

88. Julius S, Johnson EH:  Stress, autonomic hyperactivity and essential hypertension:  An enigma.  J Hypertension 3(suppl 4):S11-S18, 1985.

89. Schneider RH, Egan BM, Johnson EH, Drobny H, Julius S:  Anger and anxiety in borderline hypertension.  Psychosom Med 48:242-248, 1986.

90. Fitzpatrick MA, Hinderliter AL, Egan BM, Julius S:  Decreased venous distensibility and reduced renin responsiveness in hypertension.  Hypertension 8(Suppl II):II-36-II-43, 1986.

91. Julius S:  The emerging field of borderline hypertension.  J Cardiovasc Pharmacol 8(Suppl 5):S4-S7, 1986.

92. Julius S, Sanchez R, Brant D:  Pressure increase to external hind quarter compression in dogs:  A facultative regulatory response.  J Hypertension 4(suppl 6):  S54-S56, 1986.

93. Weder AB, Fitzpatrick MA, Torretti BA, Hinderliter AL, Egan BM, Julius S:  Red blood cell lithium-sodium countertransport as a genetic marker in essential hypertension.  J Hypertension 4(suppl 6): S373-375, 1986.

94. Egan B, Fitzpatrick MA, Julius S:  The heart and the regulation of renin.  Circulation 75(Suppl I):I-130-I-133, 1987.

95. Sanchez RA, Marco EJ, Oliveri C, Otero FJ, DeGrossi O, Moledo LI, Julius S:  Role of cardiopulmonary mechanoreceptors in the postural regulation of renin.  Am J Cardiol 59:881-886, 1987.

96. Hinderliter AL, Fitzpatrick MA, Schork N, Julius S:  Research utility of noninvasive methods for measurement of cardiac output.  Clin Pharmacol Ther 41:419-425, 1987.

97. Weder AB, Fitzpatrick MA, Torretti BA, Hinderliter AL, Egan BM, Julius S:  Red blood cell Li+-Na+ countertransport, Na+-K+ cotransport, and the hemodynamics of hypertension.  Hypertension 9 (No. 5):459-466, 1987.

98. Julius S:  Role of the sympathetic nervous system in the pathophysiology of cardiovascular disease.  American Heart Journal 114 (No. 1, Part 2):232-234, 1987.

99. Egan B, Panis R, Hinderliter A, Schork N, Julius S:  Mechanism of increased alpha-adrenergic vasoconstriction in human essential hypertension.  J Clin Invest 80:812-817, 1987.

100. Shapiro AP, Alderman MH, Clarkson TB, Furberg CD, Jesse MJ, Julius S, Miller RE, Pitt B:  Task Force 4:  Behavioral consequences of hypertension and antihypertensive therapy.  Conference on Behavioral Medicine and Cardiovascular Disease; Sea Island Proceedings.  Circulation 76 (Suppl 1):I-101 – I-103, 1987.

101. Zipes DP, Levy MN, Cobb LA, Julius S, Kaufman PG, Miller NE, Verrier RL:  Task Force 2:  Sudden cardiac death.  Neural-cardiac interactions.  Conference on Behavioral Medicine and Cardiovascular Disease; Sea Island Proceedings.  Circulation 76(Suppl 1):I-202 – I-207, 1987.

102. Julius S:  Discussion on the search for an ideal vasodilator:  A hemodynamic perspective.  J. Cardiovasc. Pharm 10 (Suppl. 1):S149-S153, 1987.

103. Schneider RH, Julius S, Moss GE, Dielman TE, Zweifler AJ, Karunas R:  New markers for Type A behavior:  pupil size and platelet epinephrine.  Psychosom Med 49:579-590. , 1987

104. Weder AB, Sekkarie MA, Takiyyuddin M, Schork NJ and Julius S:  Antihypertensive and hypotensive effects of atrial natriuretic factor in men.  Hypertension 10:582-589, 1987.

105. Julius S:  Editorial Review:  The blood pressure seeking properties of the central nervous system.  J Hypertension 6:177-185, 1988.

106. Egan B, Conlon ME, Campbell R, Schork N, Zweifler A, Julius S:  Effects of ketanserin on blood pressure and platelet aggregation in elderly men with mild hypertension.  Am J Hypertens 1:324S-330S, 1988.

107. Julius S, Brant D:  Hemodynamic plasticity during hindquarter compression.  Acta Physiologica Scandinavica 133(Supp 571):107-116, 1988.

108. Julius S, Schork N, Schork A:  Sympathetic hyperactivity in early stages of hypertension:  The Ann Arbor data set.  J Cardiovascular Pharmacology 12(Suppl. 3):S121-S129, 1988.

109. Julius S:  Transition from high cardiac output to elevated vascular resistance in hypertension.  American Heart Journal 116(No. 2,Part 2):600-606, 1988.

110. Julius S:  Interaction between renin and the autonomic nervous system in hypertension.  American Heart Journal 116 (No. 2,Part 2):611-616, 1988.

111. Sambhi MP, Chobanian AV, Julius S, Noth RH, Borhani NO, Perry HM Jr:  Mild Hypertension.  American J Med 85(5):675-696, 1988.

112. Weder AB, Takiyyuddin M, Sekkarie MA and Julius S:  Behavior and hypertension:  A pathophysiologic puzzle.  J Hypertension 7(Suppl 1):S13-S17, 1989.

113. Julius S, Li Y, Brant D, Krause L, Buda A:  Neurogenic pressor episodes fail to cause hypertension, but do induce cardiac hypertrophy.  Hypertension 13:422-429, 1989.

114. Schneider RH, Julius S, Karunas R:  Ambulatory blood pressure monitoring and laboratory reactivity in Type A behavior and components.  Psychosomatic Medicine 51:290-305,1989.

115. Mejia A, Julius S:  Practical utility of blood pressure readings obtained by self-determination.  J Hypertension 7(Suppl 3):S53-S57, 1989.

116. Julius S, Weder AB:  Brain and the regulation of blood pressure:  A hemodynamic perspective.  Clinical and Experimental Hypertension A11(Suppl.1):1-19, 1989.

117. Julius S, Gupta R:  Angiotensin converting enzyme inhibitors and the progress of antihypertensive treatment.  J Hypertension 7(Suppl 5):S23-S27, 1989.

118. Petrin J, Egan BM, Julius S:  Increased beta-adrenergic tone enhances arterial compliance in hyperkinetic borderline hypertension.  J Hypertension 7 (Suppl 6):S78-S79), 1989.

119. Schork NJ, Weder AB, Schork MA, Bassett DR, Julius S:  Disease entities, mixed multi-normal distributions, and the role of the hyperkinetic state in the pathogenesis of hypertension.  Statistics and Medicine 9:301-314, 1990.

120. Julius S:  Hemodynamic and neurohumoral evidence of multifaceted pathophysiology in human hypertension.  J Cardiovascular Pharmacology 15(Suppl. 5):S53-S58, 1990.

121. Mejia AD, Julius S, Jones KA, Schork NJ, Kneisley J:  The Tecumseh blood pressure study:  Normative data on BP self-determination.  Arch Int Med 150(6):1209-1213, 1990.

122. Julius S, Jamerson K, Mejia A, Krause L, Schork N, Jones K:  The association of borderline hypertension with target organ changes and higher coronary risk.  Tecumseh Blood Pressure Study.  JAMA 264:354-358, 1990.

123. Julius S:  Are different hemodynamic patterns of antihypertensive drugs clinically important?  Eur J Clin Pharmacol 38:S125-S128, 1990.

124. Gupta RK, Kjeldsen SE, Krause L, Kneisley J, E Posvar, Weder AB, Julius S:  Hemodynamic effects of quinapril, a novel angiotensin-converting enzyme inhibitor.  Clin Pharmacol & Ther 48:41-49, 1990.

125. Kneisley J, Schork N, Julius S:  Predictors of blood pressure and hypertension in Tecumseh, Michigan.  Clin Exp Hypertension – Theory and Practice A12(5):693-708, 1990.

126. Julius S, Mejia A, Jones K, Krause L, Schork N, van de Ven C, Johnson E, Petrin J, Sekkarie MA, Kjeldsen SE, Schmouder R, Gupta R, Ferraro J, Nazzaro P, Weissfeld J:  “White coat” versus “sustained” borderline hypertension in Tecumseh, Michigan.  Hypertension 16:617-623, 1990.

127. Julius S:  Changing role of the autonomic nervous system in human hypertension.  J Hypertens 8(7):S59-S65, 1990.

128. Julius S.  Validation of non-invasive measurement of cardiac output.  The Ann Arbor experience.  Eur Heart Journal 11(Suppl I):144-147, 1990.

129. Buhler FR, Julius S, Reaven GM: A new dimension in hypertension: role of insulin resistance.  J Cardio Pharmacology 15(Suppl 5):S1-3, 1990.

130. Julius S, Krause L, Schork NJ, Mejia AD, Jones KA, van de Ven C, Johnson EH, Sekkarie MA, Kjeldsen SE, Petrin J, Schmouder R, Gupta R, Ferraro J, Nazzaro P, Weissfeld J:  Hyperkinetic borderline hypertension in Tecumseh, Michigan.  J Hypertension 9:77-84, 1991.

131. Gupta RK, Kjeldsen SE, Motley E, Weder AB, Zweifler AJ, Julius S:  Platelet function during antihypertensive treatment with quinapril, a novel angiotensin converting enzyme inhibitor.  J Cardio Pharmacology 17:13-19, 1991.

132. Julius S, Jones K, Schork N, Johnson E, Krause L, Nazzaro P, Zemva A:  Independence of pressure reactivity from pressure levels in Tecumseh, Michigan.  Hypertension 17(Suppl III):III-12-III-21, 1991.

133. Weder AB, Schork NJ, Krause L, Julius S:  Red blood cell lithium-sodium countertransport in the Tecumseh blood pressure study.  Hypertension 17:652-660, 1991.

134. Julius S:  Autonomic nervous system dysregulation in human hypertension.  Am J Cardiol 67:3B-7B, 1991.

135. Julius S:  More on “white coat” hypertension.  Letters to the Editor.  Hypertension 17:826-827, 1991.

136. Weder AB, Schork NJ, Julius S:  Linkage of MN locus and erythrocyte lithium-sodium countertransport in Tecumseh, Michigan.  Hypertension 17:977-981, 1991.

137. Julius S, Li Y, Brant D, Krause L, Taylor D:  Quinapril, an angiotensin converting enzyme inhibitor, prevents cardiac hypertrophy during episodic hypertension.  Hypertension 17:1161-1166, 1991.

138. Buda AJ, Li Y, Brant D, Krause L, Julius S:  Changes in left ventricular diastolic filling during the development of left ventricular hypertrophy:  Observations using Doppler echocardiography in a unique canine model.  Am Heart J 121:1759-1767, 1991.

139. Julius S, Gudbrandsson T, Jamerson K, Shahab ST, Andersson O:  Hypothesis.  The hemodynamic link between insulin resistance and hypertension.  J Hypertension 9(11):983-986, 1991.

140. Julius S:  Autonomic nervous dysfunction in essential hypertension.  Diabetes Care 14 (3):249-259, 1991.

141. Jamerson K, Julius S:  Predictors of blood pressure and hypertension.  General principles.  Am J Hypertens 4:598S-602S, 1991.

142. Julius S:  Clinical implications of pathophysiologic changes in the midlife hypertensive patient.  Am. Heart J 122:886-891, 1991.

143. Julius S:  Home blood pressure monitoring:  Advantages and limitations.  J Hypertens 9 (Suppl 3):S41-S46, 1991.

144. Kjeldsen S, Gupta R, Krause L, Weder A, Julius S:  Does blood pressure reduction necessarily compromise cardiac function or renal hemodynamics? Effects of the angiotensin-converting enzyme inhibitor quinapril.  Am Heart J 123:1433-1438, 1992.

145. Julius S, Gudbrandsson T, Jamerson K, Andersson O:  The interconnection between sympathetics, microcirculation and insulin resistance in hypertension.  Blood Pressure 1: 9-19, 1992.

146. Gudbrandsson T, Julius S, Krause L, Jamerson K, Randall O, Schork N, Weder, A:  Correlates of the estimated arterial compliance in the population of Tecumseh, Michigan.  Blood Pressure 1: 27-34, 1992.

147. Jamerson K, Schork N, Julius S:  Effect of home blood pressure and gender on estimates of the familial aggregation of blood pressure; the Tecumseh blood pressure study.  Hypertension 20,3: 314-318, 1992.

148. Julius S:  Assessment of autonomic nervous function in human hypertension.  (Invited editorial) Current Opinion In Nephrology and Hypertension 1, No. 2:299-305, 1992.

149. Julius S, Gudbrandsson T:  Early association of sympathetic overactivity, hypertension, insulin resistance and coronary risk.  J Cardiovascular Pharmacology 20(Suppl. 8):S40-S48, 1992.

150. Julius S, Jamerson KA, Gudbrandsson T, Schork N:  White coat hypertension:  A follow-up.  Clin Exp Hypertens A14:45-53, 1992.

151. Julius S (Editorial):  Insulin, Insulin Resistance and Blood Pressure Elevation.  Archives of Internal Medicine 153/3:290-291, 1993.

152. Julius S:  Treatment of hypertension.  Blood Pressure 1 (Suppl 4):43-47, 1992.

153. Kjeldsen SE, Moan A, Petrin J, Weder A, Zweifler A, Julius S:  Evaluation of self-measured home vs. clinic intra-arterial blood pressure.  Blood Pressure 2, 1:28-34, 1993.

154. Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO:  Reflex sympathetic activation induces acute insulin resistance in the human forearm.  Hypertension 21, 5:618-623, 1993.

155. Julius S:  (Corcoran Lecture) Sympathetic hyperactivity and coronary risk in hypertension, Hypertension 21, 6:886-893, 1993.

156. Kjeldsen S, Petrin J, Weder A, Julius S:  Contrasting effects of epinephrine on forearm hemodynamics and arterial plasma norepinephrine.  Am J Hypertension 6, 5:369-375, 1993.

157. Julius S, Jamerson KA:  Sympathetic vasomotor tone, hemodynamics and insulin resistance in hypertension, High Blood Pressure & Cardiovascular Prevention 2:153-160, 1993.

158. Zanchetti A (Chairman), Chalmers JP, Arakawa K, Gyarfas I, Hamet P, Hansson L, Julius S, MacMahon S, Mancia G, Ménard J, Omae T, Reid J, Safar M:  The 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting, Blood Pressure 2:86-100, 1993.

159. Kingwell BA, Krause L, Julius S:  The effect of hypertensive episodes and cardiac hypertrophy on the canine cardiac baroreflex.  Clin and Exp Pharm and Physiology 21:31-39, 1994.

160. Shahab ST, Gudbrandsson T, Jamerson KA, Julius S:  Isolated “home hypertension” in Tecumseh, Michigan, Croatian Medical Journal 34(4):325-331, 1993.

161. Julius S:  Abnormalities of autonomic nervous control in human hypertension, Cardiovascular Drugs and Therapy 8:11-20, 1994.

162. Kjeldsen SE, Zweifler AJ, Petrin J, Weder AB, Julius S:  Sympathetic nervous system involvement in essential hypertension: increased platelet noradrenaline coincides with decreased ß-adrenoreceptor responsiveness, Blood Pressure 3:164-171, 1994.

163. Smith S, Julius S, Jamerson K, Amerena J, Schork N:  Hematocrit levels and physiologic factors in relationship to cardiovascular risk in Tecumseh, Michigan.  J Hypertens 12:455-462, 1994.

164. Gudbrandsson T, Julius S, Jamerson K, Smith S, Krause L, Schork N:  Recreational exercise and cardiovascular status in the rural community of Tecumseh, Michigan, Blood Pressure 3:178-184, 1994.

165. Julius S, Jamerson K:  Sympathetics, insulin resistance and coronary risk in hypertension: the ‘chicken and egg’ question.  J Hypertens 12:495-502, 1994.

166. Marcus R, Krause L, Weder AB, Dominguez-Mejia A, Schork NJ, Julius S:  Sex-specific determinants of increased left ventricular mass in the Tecumseh blood pressure study.  Circulation 90:928-936, 1994.

167. Jamerson K, Smith SD, Amerena JV, Grant E, Julius S:  Vasoconstriction with norepinephrine causes less forearm insulin resistance than a reflex sympathetic vasoconstriction.  Hypertension 23(6):1006-1011, 1994.

168. Julius S:  La interrelación entre hiperactividad simpática y resistencia a la insulina en la hipertensión humana; un dilema fisiopatológico.  J Hypertens, Edición Española 1(Suppl 1):S27-S34, 1994.

169. Julius S:  The defense reaction: a common denominator of coronary risk and blood pressure in neurogenic hypertension?  Clin and Exper Hypertension 17(1&2):375-386, 1995.

170. Julius S:  Sympathetic overactivity and the pathophysiology of the coronary risk in hypertension.  Cardiovascular Risk Factors 5(Suppl 1):2-10, 1995.

171. Kjeldsen SE, Weder AB, Egan B, Neubig R, Zweifler AJ, Julius S:  Effect of circulating epinephrine on platelet function and hematocrit.  Hypertension 25(5):1096-1105, 1995.

172. Amerena J, Julius S:  The role of the autonomic nervous system in hypertension.  (An invited review) Hypertension Research 18(2):99-110, 1995.

173. Julius S, Nesbitt S:  Sympathetic nervous system as a coronary risk factor in hypertension.  Cardiologia 41(4):309-317, 1996.

174. Julius S:  The evidence for a pathophysiologic significance of the sympathetic overactivity in hypertension.  Clin and Exp Hypertens 18(3&4):305-321, 1996.

175. Jamerson J, Nesbitt S, Amerena J, Grant E, Julius S:  Angiotensin mediates forearm glucose uptake by hemodynamic rather than direct effects.  Hypertension 27:854-858 1996.

176. Kjeldsen SE, Moan A, Petrin J, Weder AB, Julius S:  Effects of increased arterial epinephrine on insulin, glucose and phosphate.  Blood Pressure 5:25-31, 1996.

177. Amerena J, Julius S:  The role of the sympathetic nervous system in hypertension.  Cardiol Rev 4(6):340-352, 1996.

178. Julius S, Nesbitt S:  Sympathetic overactivity in hypertension.  A moving target.  Am J Hypertens 9:113S-120S, 1996.

179. Palatini P, Julius S:  Heart rate and the cardiovascular risk.  J Hypertens 15:1-15, 1997.

180. Vriz O, Nesbitt S, Krause L, Majahalme S, Lu H, Julius S:  Smoking is associated with higher cardiovascular risk in young women than in men: the Tecumseh Blood Pressure Study.  J Hypertens 15:127-134, 1997.

181. Julius S:  Coronary disease in hypertension: a new mosaic.  J Hypertens 15(suppl 2):S3-S10, 1997.

182. Amerena J, Julius S:  Sympathetic overactivity and coronary risk in hypertension.  Fundam Clin Pharmacol 11(suppl 1):78s-81s, 1997.

183. Amerena J, Nesbitt S, Krause L, Grant E, Lu H, Julius S:  Trends in left ventricular function over three years in the Tecumseh study.  Blood Pressure 6:262-268, 1997.

184. Palatini P, Julius S:  Association of tachycardia with morbidity and mortality: pathophysiological considerations.  J Human Hypertens 11(suppl 1):S19-S27, 1997.

185. Dahlof B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H.  The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study: rationale, design, and methods.  The LIFE Study Group.  Am J Hypertens 10(7 Part 1):705-713, 1997.

186. Julius S, Valentini M:  Continuing on J.P. Henry’s path; studies of physiology and pathophysiology of cardiopulmonary receptors in humans.  Acta Physiol Scand 161(suppl 640):122-124, 1997.

187. Nesbitt SD, Amerena JV, Grant E, Jamerson KA, Lu H, Weder A, Julius S:  Home blood pressure as a predictor of future blood pressure stability in borderline hypertension.  The Tecumseh Study.  Am J Hypertens 10:1270-1280, 1997.

188. Palatini P, Casiglia E, Pauletto P, Staessen J, Kaciroti N, Julius S:  Relationship of tachycardia with high blood pressure and metabolic abnormalities.  A study with mixture analysis in three populations.  Hypertension 30:1267-1273, 1997.

189. Julius S:  Current trends in the treatment of hypertension: A mixed picture.  Am J Hypertens 10:300S-305S, 1997.

190. Palatini P, Julius S, Collatina S, Rappelli S, Staessen, Pessina AC on behalf of the HAROLD study investigators:  Optimizing the assessment of the elderly patient with borderline hypertension:  the Hypertension and Ambulatory Recording in the OLD (HAROLD) study.  Aging Clin Exp Res 9:365-371, 1997.

191. Julius S, Palatini P, Nesbitt S:  Tachycardia: an important determinant of coronary risk in hypertension.  J Hypertens 16:S9-S15, 1998.

 

192. Neel JV, Julius S, Weder A, Yamada M, Kardia SLR, Haviland MB:  Syndrome X:  is it for real?  Gen Epidem 15:19-31, 1998.

193. Thijs L, Staessen JA, Celis H, de Gaudemaris R, Imai Y, Julius S, Fagard R:  Reference values for self-recorded blood pressure: a meta-analysis of summary data.  Arch Intern Med 158:481-488, 1998.

194. Julius S, Nesbitt S:  Clinical consequences of the autonomic imbalance in hypertension and congestive heart failure.  Scand Cardiovasc J 32:23-30, 1998.

195. Kjeldsen SE, Hedner T, Jamerson K, Julius S, Haley WE, Zabalgoitia M, Butt AR, Rahman SN, Hansson L, for the HOT Study Group:  Hypertension Optimal Treatment (HOT) study.  Home blood pressure in treated hypertensive subjects.  Hypertension 31:1014-1020, 1998.

196. Hansson L, Zanchetti A, Carruthers SG, Dahlöff B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S for the HOT Study Group:  Effects of intensive blood-pressure lowering and acetylsalicylic acid in patients with hypertension:  principal results of the Hypertension Optimal Treatment (HOT) randomised trial.  Lancet 351:1755-1762, 1998.

197. Julius S:  Effect of sympathetic overactivity on cardiovascular prognosis in hypertension.  Eur Heart J 19:F14-F18, 1998.

198. Mann J, Julius S for the VALUE Trial Group:  The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension.  Rationale and design.  Blood Pressure 7:176-183, 1998.

199. Young EA, Nesse RM, Weder A, Julius S:  Anxiety and cardiovascular reactivity in the Tecumseh population.  J Hypertens 16:1727-1733, 1998.

200. Weber MA, Julius S (Editorial):  The challenge of very mild hypertension.  Should treatment be sooner or later?  Am J Hypertens 11:1495-1496, 1998.

201. Dahlöff B, Devereux, RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE Study Group:  Characteristics of 9194 patients with left ventricular hypertrophy.  The LIFE study.  Hypertension 32:989-997, 1998.

202. Neel JV, Weder AB, Julius S:  Type II diabetes, essential hypertension, and obesity as “syndromes of impaired genetic homeostasis”: the “thrifty genotype” hypothesis enters the 21st century.  Persp Biol Med 42:44-74, 1998.

203. Julius S, Valentini M: Consequences of the increased autonomic nervous drive in hypertension, heart failure and diabetes.  Blood Pressure. Suppl 3:5-13, 1998.

204. Palatini P, Julius S:  The physiological determinants and risk correlations of elevated heart rate.  Am J Hypertens 12(1, part 2):3S-8S, 1999.

205. Palatini P, Casiglia E, Julius S, Pessina AC:  High heart rate.  A risk factor for cardiovascular death in elderly men.  Arch Intern Med 159:585-592, 1999.

206. Palatini P, Julius S:  Relevance of heart rate as a risk factor in hypertension.  Curr Hypertens Rpts 3:219-224, 1999.

207. Palatini P, Vriz O, Nesbitt S, Amerena J, Majahalme S, Valentini M, Julius S:  Parental hyperdynamic circulation predicts insulin resistance in offspring.  The Tecumseh study.  Hypertension 33:769-774, 1999.

208. Julius S:  Borderline hypertension.  Clin and Exper Hypertension 21(5&6):741-747, 1999.

209. Julius S:  Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension:  The VALUE trial.  Cardiology 91(suppl 1):8-13, 1999.

210. Thijs L, Staessen JA, Celis H, Fagard R, De Cort P, de Gaudemaris R, Enström I, Imai Y, Julius S, Ménard J, Mion D, Palatini P, Rosenfeld J, Shapiro D, Spence D, Stergiou G:  The international database of self-recorded blood pressures in normotensive and untreated hypertensive subjects.  Blood Pressure Monitoring 4:77-86, 1999.

211. Julius S, Brunner H:  Challenging the paradigm for treatment of hypertension: focus on elevated systolic blood pressure – Introduction.  Am Heart J 138(3):S203-S204, 1999.

212. Olsen MH, Fossum E, Hjerkinn E, Wachtell K, Hoieggen A, Nesbitt SD, Andersen UB, Phillips RA, Gaboury CL, Ibsen H, Kjeldsen SE, Julius S:  Relative influence of insulin resistance versus blood pressure on vascular changes in longstanding hypertension.  ICARUS, a LIFE substudy.  J Hypertens 18:75-81, 2000.

213. Julius S:  Trials of antihypertensive treatment – new agenda for the millennium.  Am J Hypertens 13:11S-17S, 2000.

214. Julius S, Valentini M, Palatini P:  Overweight and hypertension.  A 2-way street?  Hypertension 35:807-813, 2000.

215. Yarows SA, Julius S, Pickering TG:  Home blood pressure monitoring.  Arch Intern Med 160:1251-1257, 2000.

216. Julius S:  Worldwide trends and shortcomings in the treatment of hypertension.  Am J Hypertens 13(5, part 2):57S-61S, 2000.

217. Nesbitt S, Julius, S:  Prehypertension: A possible target for antihypertensive medication.  Curr Hypertens Rpts 2:356-361, 2000.

218. Palatini P, Majahalme S, Amerena J, Nesbitt S, Vriz O, Michieletto M, Krause L, Julius S:  Determinants of left ventricular structure and mass in young subjects with sympathetic over-activity.  The Tecumseh offspring study.  J Hypertens 18:769-775, 2000.

219. Brook RD, Julius S:  Autonomic imbalance, hypertension, and cardiovascular risk.  Am J Hypertens 13(6, part 2):112S-122S, 2000.

220. Julius S:  Five decades of antihypertensive treatment: the unresolved issues.  J Hypertens 18(Suppl 3):S3-S7, 2000.

221. Kjeldsen SE, Dahloff B, Devereux RB, Julius S, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen, O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel, for the LIFE study group:  Lowering of blood pressure and predicators of response in patients with left ventricular hypertrophy: the LIFE study.  Am J Hypertens 13:899-906, 2000.

222. Julius S, Majahalme S:  The changing face of sympathetic overactivity in hypertension.  Ann Med 32:365-370, 2000.

223. Okin PM, Devereux, RB, Jern S, Kjeldsen SE, Julius S, Dahloff B for the LIFE Study Investigators:  Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients.  The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study.  Hypertension 36:766-773, 2000.

224. Julius S: New Clinical Trials of Angiotensin Blockade in Cardiovascular Disease: Foreward.  Am J Hypertens 13(5, part 2):55S, 2000.

225. Kjeldsen SE, Julius S, Brunner H, Hansson L, Henis M, Ekman S, Laragh J, McInnes G, Smith B, Weber M, Zanchetti A for the VALUE Trial Group:  Characteristics of 15314 hypertensive patients at high coronary risk.  The VALUE Trial.  Blood Pressure 10:83-91, 2001.

226. Palatini P, Krause L, Amerena J, Nesbitt S, Majahalme S, Tikhonoff V, Valentini M, Julius S:  Genetic contribution to the variance in left ventricular mass: the Tecumseh Offspring Study.  J Hypertens 19:1217-1222, 2001.

227. Okin PM, Devereux RB, Jern S, Julius S, Kjeldsen SE, Dahlof B, for the LIFE Study Investigators:  Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE study.  Am J Hypertens 14:775-782, 2001.

228. Okin PM, Devereux RB, Nieminen MS, Jern S, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Julius S, Dahlöf B, for the LIFE Study Investigators:  Relationship of electrocardiographic strain pattern to left ventricular structure and function in hypertensive patients: the LIFE study.  JACC 38:412-520, 2001.

229. Julius S, Majahalme S, Palatini P:  Antihypertensive treatment of patients with diabetes and hypertension.  Am J Hypertens 14:310S-316S, 2001.

230. Reims H, Fossum E, Kjeldsen SE, Julius S:  Home blood pressure monitoring.  Current knowledge and directions for future research.  Blood Pressure 10:271-287, 2001.

231. Kjeldsen SE, Julius S, Hedner T, Hansson L: Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials.  Blood Pressure 10:190-192, 2001

232. Julius S:  The association of tachycardia with obesity and elevated blood pressure.  J Pediatr. 140(6):643-5, 2002.

233. Parati G, de Leeuw P, Illyes M, Julius S, Kuwajima I, Mallion JM, Ohtsuka K, Imai Y, Blood pressure measurement in research. Blood Pressure Monitoring. 7(1):83-87, 2002.

234. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G,  de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H for the LIFE study group:  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol.  Lancet 359:995-1003, 2002.

235. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, for the LIFE study group:  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.  Lancet 359: 1004-10, 2002.

236. Julius S, Majahalme S, Nesbitt, Grant E, Kaciroti N, Ombao H, Vriz, Valentini M, Amerena J and Gleiberman L:  A “gender blind” relationship of lean body mass and blood pressure in the Tecumseh, study.  Am J Hypertens 15:258-263, 2002.

237. Okin PM, Wright JT, Nieminen MS, Julius S, Devereux RB for LIFE Study Investigators, et al: Ethnic Differences in Electrocardiographic Criteria for Left Ventricular Hypertrophy:  The LIFE Study.  Am J Hypertens;15,663-71, 2002.

238. Palatini P, Amerena J, Nesbitt S, Valentini M,  Majahalme S, Krause L, Tikhonoff V and  Julius S: Heritability of left atrial size in the Tecumseh population. European Journal of Clinical Investigation 32(7):467–471, 2002.

239. Skov K, Julius S, Nesbitt S, Mulvany MJ: Can hypertension be prevented? The Danish Hypertension Prevention Project and the Trial of Prevention of Hypertension studies. Current Opinion in Cardiology;17:380–384, 2002.

240. Kjeldsen SE, Dahlof B, Devereux RB, Julius S, et al:  Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients with Isolated Systolic Hypertension and Left Ventricular Hypertrophy.  JAMA 288(12):1491-8, 2002.

241. Palatini P, Julius S:  Pathophysiology of the Association between Increased Heart Rate and Cardiovascular Morbidity and Mortality.  Medicographia; 24(3):201-6, 2002.

242. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, Devereux RB, Julius S, Kjeldsen SE, etal. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens;20(9);1879-86, 2002.

243. Zanchetti A, Hansson L, Dahlöf B, Julius S, Ménard J; Warnold I, Wedel H, on behalf of the HOT Study Group:  Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk J Hypertens 20(11): 2301-2307, 2002.

244. Julius S: Lennart Hansson, MD – In memoriam. Hypertension. 41(1):1-2, 2003.

245. Julius S: The ALLHAT study: if you believe in evidence-based medicine, stick to it! J Hypertens. 21(3):453-454, 2003.

246. Julius S: Bringing VALUE to LIFE. European Heart Journal Supplements. 5(C):C5-C8, 2003.

247. Zanchetti A, Hansson L, Clement D, Elmfeldt D, Julius S, Rosenthal T, Waeber B, Wedel H: HOT Study Group. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers?  J Hypertens. 21(4):797-804, 2003.
248. Julius S:  Of rat and man.  J Hypertens 21(4):705-6, 2003.

249. Olsen MH, Hjerkinn E, Wachtell K, Hoieggen A, Bella JN, Nesbitt SD, Fossum E, Kjeldsen SE, Julius S, Ibsen H:  Are left ventricular mass, geometry and function related to vascular changes and/or insulin resistance in long-standing hypertension? ICARUS: a LIFE substudy.  J Human Hypertension. 17(5):305-11, 2003.

250. Julius S, Kjeldsen SE, Brunner H, Hansson L, Platt F, Ekman S, Laragh JH, McInnis G, Schork AM, Smith B, Weber M, Zanchetti A:  VALUE Trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk.  Am J Hypertens 16(7):544-8, 2003.

251. Devereux RB, Dahlof B, Kjeldsen SE, Julius S, Aurup P, Beevers G, Edelman JM, de Faire U, Fyhrquist F, Helle Berg S, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H:  LIFE Study Group. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.  Ann Int Med. 139(3):169-77, 2003.

252. Okin PB, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlof B:  Losartan Intervention for Endpoint reduction in hypertension Study Investigations. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.  Circulation. 108(6):684-90, 2003.

253. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P:  Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.  Ann Int Med. 139(11):901-6, 2003.

254. Julius S, Cohn JN, Neutel J, Weber M, Turlapaty P, Shen Y, Dong V, Batchelor A, Lagast H:  Antihypertensive utility of perindopril in a large, general practice-based clinical trial.  J Clinical Hypertens (Greenwich) 6(1):10-17, January, 2004.

255. Cohn JN, Julius S, Neutel J, Weber M, Turlapaty P, Shen Y, Dong V, Batchelor A, Guo W, Lagast H:  Clinical experience with perindopril in African-American hypertensive patients: a large United States community trial. Am J Hypertens. 17(2):134-8, Feb. 2004.

256. Hoieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS:  Omvik P. Oparil S. Wedel H. Chen C. Dahlof B; LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study.  Kidney Int. 65(3):1041-1049, March 2004.

257. Julius S, Alderman MH, Beevers G, Dahlöf B, Devereux RB, Douglas JG, Edelman JM, Harris KE, Kjeldsen SE, Nesbitt S, Randall OS, Wright, Jr. JT:  Cardiovascular Risk Reduction in Hypertensive Black Patients with Left Ventricular Hypertrophy.  JACC. 43(6):1047-1055, March 2004.

258. Fossum E, Olsen MH, Høieggen A, Wachtell K, Reims HM, Ibsen H, Julius S, Kjeldsen SE: Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy.  J Human Hypertens. 18:375-380, June 2004.

259. Reims HM, Kjeldsen SE, Brady WE, Dahlöf B, Devereaux RB, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pederson O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H for the LIFE study group: Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study.  J Human Hypertens, Special LIFE issue. 18:381-389, April 2004.

260. Okin PM, Devereaux RB, Liu JE, Oikarinen L, Jern S, Kjeldsen SE, Julius S, Wachtell K, Nieminen MS, Dahlöf: Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study. J Human Hypertens. 18:403-409, April 2004.

261. Julius S, Kjeldsen, SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork MA, Smith B, Zanchetti A, for the VALUE trial group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial.  Lancet. 363:2022-31, June 2004.

262. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh JH, McInnes GT, Mitchell L, Plat F, Shork MA, Smith B, Zanchetti A: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial.  Lancet. 363:2049-51, June 2004.

263. Okin PM, Devereux RB, Nieminen MS, Jern S, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Julius S, Snapinn S, Dahlof B, for the LIFE Study Investigators: Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients.  Hypertension. 44:48-54, July 2004.

264. Julius S, Nesbitt S, Egan B, Kaciroti N, Schork MA, Grozinski M, Michelson E, for the TROPHY study group: Trial of preventing hypertension, Design and 2-year progress report.  Hypertension. 44:146-151, August 2004.

265. Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Morgensen CE, Dahlöf B, Devereaux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y: Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.  J Hypertens. 22:1805-1811, Sept. 2004.

266. Valentini M, Julius S, Palatini P, Brook RD, Bard RL, Bisognano JD, Kaciroti N: Attenuation of  haemodynamic, metabolic and energy expenditure responses to isoproterenol in patients with hypertension. J Hypertens. 22:1999-2006, July 2004.

267. Neutel JM, Weber MA, Julius S, Cohn JN, Turlapaty P, Shen Y, Guo W, Batchelor A, Lagast H: Clinical experience with perindopril in elderly hypertensive patients.  A subgroup analysis of a large community trial.  Am J Cardiovasc Drugs. 4 (5):335-341, July 2004.

268. Høeggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, Fyhrquist J, Ibsen H, Kristianson K, Lederball-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Chen C, Dahlöf B, for the LIFE study group: The impact of serum uric acid on cardiovascular outcomes in the LIFE study.  Kidney International. 65:1041-1049, September 2004.

269. Kjeldsen SE, Julius S: Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.  Am Heart. 148:747-54, November 2004.
270. Egan BM, Julius S: Role of sympathetic overactivity in the pathophysiology of the metabolic syndrome.  Dialogues Cardiovasc Med. 9:143-157, November 2004.
271. Reims HM, Oparil S, Kjeldsen SE, Devereux RB, Julius S, Brady WE, Fyhrquist F, Ibsen H, Lindholm LH, Omvik P, Wedel H, Beevers G, de Faire U, Kristianson K, Lederballe-Pederson O, Nieminen M, Dahlöf B, for the LIFE Study Group: Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study.  Blood Pressure. 13:376-384, November 2004.
272. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B, for the LIFE Study Investigators: Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 292:2343-2349, November 2004.
273. Palatini P, Julius S: Elevated heart rate: a major risk factor for cardiovascular disease.  Clinical & Experimental Hypertension. 26(7-8):637-44 November 2004.
274. Kizer JR, Dahlöf B, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Wachtell K, Edelman JM, Snapinn SM, Harris KE, Devereux RB: Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus  atenolol.  The losartan intervention for endpoint reduction in hypertension study. Hypertension. 45:46-52, January 2005.
275. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Morgensen CK, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pederson O, Nieminen MS, Omvik P, Oparil S, Wan Y: Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients.  Losartan intervention for endpoint reduction in hypertension study.  Hypertension. 45:198-202, February 2005.
276. Egan BM, Papademetriou V, Wofford M, Calhoun D, Fernandes J, Riehle JE, Nesbitt S, Michelson E, Julius S, for the TROPHY sub-study investigative team:  Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure.  Am J Hypertens. 18: 3-12, January 2005.
277. Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB: Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation.  The losartan intervention for end point reduction in hypertension (LIFE) study.  J Am Coll Cardiol. 45:705-11, March 2005.
278. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB: Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol.  The losartan intervention for end point reduction in hypertension (LIFE) study.  J Am Coll Cardiol. 45:712-9, March 2005.
279. Kjeldsen SE, Lyle PA, Kiser JR, Dahlöf B, Devereux RB, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn SM, Harris KE, Wedel H, for the LIFE Study Group: The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy.  J Clinical Hypertension. 7:152-158, March, 2005.
280. Fyhrquist F, Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Hille DA, Lyle PA, Edelman JM, Snapinn SM, Wedel H; for the LIFE Study Group:  Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.  Hypertens. 45:580-585, April 2005.
281. Olsen MH, Fossum E, Høeiggen A, Wachtell K, Hjerkinn E, Nesbitt SD, Andersen UB, Phillips RA, Gaboury CL, Ibsen H, Kjeldsen SE, Julius S: Long term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy.  J of Hypertens. 23:891-898, April 2005.
282. de Simone G, Wachtell K, Palmieri V, Hille DA, Beevers G, Dahlöf B, de Faire U, Fyhrquist F,  Ibsen H, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Devereux RB: Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy.  The LIFE (Losartan intervention for endpoint reduction in hypertension) study.  Circulation. 111:1924-1931, April 2005.
283. Nesbitt SD, Julius S, Leonard D, Egan BM, Grozinski M, for the TROPHY Study Investigators: Is low-risk hypertension fact or fiction?  Am J Hypertens. 18:980-985, July 2005.
284. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y:  Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients.  Hypertension 45:198-202, 2005.
285. Fossum E, Moan A, Kjeldsen SE, Devereux RB, Julius S, Snapinn SM, Edelman JM, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Dahlöf B, for the LIFE Study Group: The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin.  J Am Coll Cardiol 46:770-5, Sept. 2005.
286. Palatini P, Benetos A, Julius S: Impact of increased heart rate on clinical outcomes in hypertension.  Drugs 66(2):133-144, 2006.
287. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH Jr, Messerli FH, Oparil S, Schork MA for the Trial of Preventing Hypertension (TROPHY) Study Investigators:  Feasibility of treating prehypertension with an angiotensin-receptor blocker.  N Engl J Med 354:1685-97, April 2006.
288. Okin PM, Devereux RB, Gerdts E, Snapinn SM, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Lindholm LH, Dahlöf B, for the LIFE Study Investigators: Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy.  The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.  Circulation 113:1588-96, March 2006.
289. Fossum E, Olsen MH, Høieggen A, Wachtell K, Reims HM, Kjeldsen SE, Ibsen H, Wan Y, Julius S:  Long-term effects of a losartan-compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy.  J Clin Hypertens 8:169-173, April 2006.
290. Palatini P, Benetos A, Grassi G, Julius S, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Pessina AC, Ruilope LM, Zanchetti A:  Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting.  J Hypertens 24:603-610, April 2006.
291. Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, Weber MA, Coca A, Ekman S, Girerd X, Jamerson K, Larochelle P, MacDonald TM, Schmeider RE, Schork MA, Stolt P, Viskoper R, Widimsky J, Zanchetti A; for the VALUE Trial Investigators.  Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.  J Hypertens 24(7):1405-1412, July 2006.
292. Kjeldsen SE, Strand A, Julius S, Okin PM.  Mechanism of angiotensin II type 1 receptor blocker action in the regression of left ventricular hypertrophy.  J Clin Hypertens 8:487‑492, July 2006.
293. Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A, Brunner HR, Laragh J, Schork MA, Hua TA, Amerena J, Balazovjech I, Cassel G, Herczeg B, Koylan N, Magometschnigg D, Majahalme S, Martinez F, Oigman W, Seabra Gomes R, Zhu JR.  The valsartan antihypertensive long-term use evaluation (VALUE) trial.  Outcomes in patients receiving monotherapy.  Hypertens 48:385-391, March 2006.
294. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Lindholm LH, Nieminen MS, Edelman JM, Hille DA, Dahlöf B.  Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 296:1242-1248, September 2006.
295. Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, Laragh JH, Plat F, Battegay E, Calvo-Vargas C, Cieslinski A, Degaute JP, Holwerda NJ, Kobalava J, Pedersen OL, Rudyatmoko FP, Siamopoulos KC, Storset O:  Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial.  J Hypertens 24(11):2163-2168, 2006
296. Pedersen OL, Mancia G, Pickering T, Hoegholm A, Julius S, Kjeldsen SE, Nielsen ES, Refsgaard J, Weber M, for the VALUE trial group: Ambulatory blood pressure monitoring after 1 year on valsartan or amlodipine-based treatment: a VALUE substudy. J Hypertens 25(3):707-712, 2007.
297. Mancia G, Bousquet P, Elghozi JL, Esler M. Grassi G, Julius S, Reid J, Van Zwieten PA: The sympathetic nervous system and the metabolic syndrome. J Hypertens 25:909-920, 2007.
298. Julius S. Should the results of TROPHY affect the JNC definition of prehypertension?  Current Hypertension Reports, 9:202-205, 2007.
299. Fossum E, Gleim GW, Kjeldsen SE, Kizer JR, Julius S, Devereux RB, Brady WE, Hille DA, Lyle PA, Dahlöf B.  The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.  J Internal Medicine, 262(4):439-448, 2007.
300. Ruilope LM, Zanchetti A, Julius S, McInnes GT, Segura J, Stolt P, Hua TA, Weger MA, Jamerson K, for the VALUE Investigators.  Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial.  J Hypertens, 25:1473-1479, 2007.
301. Julius S. Blood pressure lowering only or more?  Has the jury reached its verdict?  Am J Cardiol, 100[suppl]:32J-37J, 2007.
302. Aksnes TA, Kjeldsen SE, Rostrup M, Omvik P, Hua TA, Julius S. Impact of new-onset diabetes mellitus on cardiac outcomes in the valsartan antihypertensive long-term use evaluation (VALUE) trial population.  Hypertension, 50:467-473, 2007.
303. Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Dahlöf B, for the LIFE Study Investigators.  Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann Intern Med.  147:311-319, 2007.
304. Julius S, Kaciroti N, Egan BM, Nesbitt S, Michelson EL for the Trial of Preventing Hypertension (TROPHY) Investigators.  TROPHY Study: Outcomes based on the Seventh Report of the Joint National Committee on Hypertension definition of hypertension.  Journal of the American Society of Hypertension 2(1):39-43, 2008.
305. Okin PM, Wachtell K, Devereux RB, Nieminen MS, Oikarinen L, Vitasalo M, Toivonen L, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Kjeldsen SE, Julius S, and Dahlöf B, for the LIFE Study Investigators.  Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: The LIFE Study. Am J Hypertens 21:273-279, 2008.
306. Aksnes TA, Schmieder, RE, Kjeldsen SE, Ghani S, Hua TA, Julius S.  Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high risk hypertension (from the VALUE trial). Am J Cardiol 101:634-638, 2008.
307. Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA, for the VALUE trial group.  Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial.  J Hypertens 26:403-411, 2008.
308. Oparil S, Abate N, Chen E. Creager MA, Galet V, Jia G, Julius S, Lerman A, Lyle PA, Pool J, Tershakovec AM. A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension.  Current Medical Research and Opinion 24(4):1101-1114, 2008.
309. Okin PM, Gerdts E, Kjeldsen SE, Julius S, Edelman JM, Dahlöf B, Devereux RB, for the Losartan Intervention for Endpoint Reduction in Hypertension Study Investigators.  Gender differences in regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy.  Hypertension 52:1-7, 2008.
310. Williams SA, Michelson EL, Cain VA, Yang M, Nesbitt SD, Egan BM, Julius S, for the TROPHY Study Investigators.  An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY). J Clin Hypertens, 10:436-442, 2008.
311. Aksnes TA, Rostrup M, Kjeldsen SE, Störset Ø, Hua A, Julius S. Predictors of new-onset diabetes mellitus in high risk hypertensive patients in the Value Trial. J Hum Hypertens  22(8):520-7, 2008.
312. Messerli FH, Bangalore S, Julius S.  Risk/benefit assessment of β-blocker and diuretics precludes their use for first line therapy in hypertension. Circulation 117:2706-2715, 2008.
313. Kjeldsen SE, McInnes GT, Mancia G, Hua TA, Julius S, Weber MA, Coca A, Girerd X, Jamerson K, Larochelle P, Macdonald T, Schmieder RE, Schork MA, Viskoper R, Widimsky J, Zanchetti A. for the VALUE Trial Investigators.  Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial.  Blood Pressure 17:170-177, 2008.
314. Egan BM, Nesbitt SD, Julius S. Prehypertension: should we be treating with pharmacologic therapy?  Therapeutic Advances in Cardiovascular Disease, 2(4), 305-314, 2008.
315. Egan BM, Julius S.  Prehypertension: risk stratification and management considerations.  Current Hypertension Reports, 10:359-366, 2008.
316. Okin PM, Wachtell K, Kjeldsen SE, Julius S, Lindholm LH, Dahlöf B, Hille DA, Nieminen MS, Edelman JM, Devereux RB.  Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE Study.  Circ Arrhythmia Electrophysiol 1;337-343, 2008.
317. Aksnes TA, Tjugen TB, Schmieder RE, Kjeldsen SE, Julius S.  Impact of diabetes development on atrial fibrillation in hypertensive patients.  Cardiology Review 25:44-47, 2008.
318. Sasamura H, Nakaya H, Julius S, Takebayashi T, Sato Y, Uno H, Takeuchi M, Ishiguro K, Murakami M, Ryuzaki M, Itoh H, STAR CAST Investigators.  The short treatment with the angiotensin receptor blocker candesartan surveyed by telemedicine (STAR CAST) study: rationale and study design.  Hypertension Research – Clinical & Experimental. 31(10):1843-9, 2008.
319. Palatini P, Parati G, Julius S.  Office and out of office heart rate measurements: which clinical value?  J Hypertens 26:1540-1545, 2008.
320. Kaciroti NA, Schork MA, Raghunathan T, Julius S.  A Bayesian sensitivity model for intention-to-treat analysis on binary outcomes with dropouts.  Statist. Med. 28:572-585, 2009.
321. Julius S. Prehypertension in China.  J Hypertens 27:700-701, 2009.
322. Palatini P, Julius S. The role of cardiac autonomic function in hypertension and cardiovascular disease.  Current Hypertension Reports 11:199-205, 2009.
323. Julius S. Tachycardia in hypertension; a saga of progress despite prejudice, confusion and inertia.  Prog Cardiovasc Dis 52:26-30, 2009.
324. Aksnes TA, Kjeldsen SE, Julius S.  Atrial fibrillation and hypertension. Arch Med Sci 5, 2A:S 267-272, 2009.
325. Feldstein C, Julius S. The complex interaction between overweight, hypertension and sympathetic overactivity.  JASH 3;6:353-365, 2009.
326. Kjeldsen SE, Devereux RB, Hille DA, Lyle PA, Dahlöf B, Julius S, Edelman JM, Snapinn SM, De Faire U, Fyhrquist F, Ibsen H, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H.  Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. Blood Pressure, 18;6:348-361, 2009.
327. Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahlöf B, Edelman JM, Devereux RB.  All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy.  Eur Heart J.  31:2271-2279, 2010.
328. Feldstein C, Julius S. Establishing targets for hypertension control in patients with comorbidities.  Curr Hypertens Rep 12:465-473, 2010.
329. Julius S, Kjeldsen SE, Weber MA. Angiotensin-receptor blockade, cancer and concerns. Lancet Oncology 1(9):820-1, 2010.
330. The ARB Trialists Collaboration.  Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.  Journal of Hypertension 29:623-635, 2011.
331. Pitt B, Julius S.  Easy money? Health cost savings resulting from the switch from a branded drug to a low-cost generic drug in the same class. International Journal of Clinical Practice 65(3):242-4, 2011.
332. Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahlöf B, Devereux RB.  Effect of changing heart rate during treatment of hypertension on incidence of heart failure.  Am J Cardiol  Mar 1;109(5):699-704, 2012. Epub 2011 Dec 10.
333. Julius S, Palatini P, Kjeldsen SE, Zanchetti A, Weber MA, McInnes GT, Brunner HR, Mancia G, Schork MA, Hua TA, Holzhauer B, Zappe D, Majahalme S, Jamerson K, Koylan N.  Usefulness of Heart rate to predict cardiac events in treated patients with high risk systemic hypertension.  Am J Cardiol 109:685-692, 2012.
334. Kaciroti NA, Raghunathan TE, Taylor JMG, Julius S.  A Bayesian model for time-to-event data with informative censoring.  Biostatistics (in print 2012).
335. Okin PM, Kjeldsen SE, Julius S, Dahlöf B, Devereux RB.  Racial differences in sudden cardiac death among hypertensive patients during antihypertensive therapy: The LIFE study.  Heart Rhythm, 9(4) 531-537, 2012.
336. Weber MA, Julius S, Kjeldsen SE, Jia Y, Brunner HR, Zappe DH,. Hua TA, McInnes GT, Schork A, Mancia G, Zanchetti A.  Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy. Journal of Hypertension.  30:2213-2222, 2012.
337. Levitan EB, Kaciroti N, Oparil S, Julius S, Muntner P.  Blood pressure measurement device, number and timing of visits, and intra-individual visit-to-visit variability of blood pressure.  J Clin Hypertens (Greenwich). 14:744-750, 2012.
338. Julius S, Kaciroti N, Oparil S. Reply to visit-to-visit blood pressure variation: time to reanalyze all the data from the TROPHY study.  Journal of Clinical Hypertension 15(4):301, 2013.
339. Levitan, EB, Kaciroti N, Oparil S, Julius S, Muntner P. Relationships between metrics of visit-to-visit variability of blood pressure.  Journal of Human Hypertension 2013 Oct;27(10):589-93.
340. Sasamura H, Nakaya H, Julius S, Tomotsugu N, Sato Y, Takahashi F, Takeuchi M, Murakami M, Ryuzaki M, Itoh H; STAR CAST investigators.  Feasibility of regression of hypertension using contemporary antihypertensive agents.  Am J Hypertens. 2013 Dec;26(12):1381-8.
341. Julius S, Egan BM, Kaciroti NA, Nesbitt SD, Chen AK. for TROPHY investigators. In prehypertension leukocytosis is associated with body mass index but not with blood pressure or incident hypertension.   J Hypertens.  2014. Feb 32(2):251-9.
342. Okin PM, Bang CN, Wachtell K, Hille DA, Kjeldsen SE, Julius S, Dahlof B, Devereux RB.  Racial differences in incident atrial fibrillation among hypertensive patients during antihypertensive therapy. Am J Hypertens 2014, 27(7):966-72.
343. Ference BA, Julius S, Mahajan N, Levy PD, Williams KA Sr, Flack JM. Clinical effect of naturally random allocation to lower systolic blood pressure beginning before the development of hypertension.  Hypertension.  2014.  63(6):1182-88.
344. Kjeldsen SE, Julius S, Dahlӧf B, Weber MA.  Physician (investigator) inertia in apparent treatment-resistant hypertension – Insights from large randomized clinical trials.  Blood Pressure, 2015. 24(1):1-6.
345. Sandset EC, Berge E, Kjeldsen SE, Julius S, Holzhauer B, Krarup LH, Hua TA.  Heart Rate as a Predictor of Stroke in High-risk, Hypertensive Patients with Previous Stroke or Transient Ischemic Attack.  Journal of Stroke and Cerebrovascular Diseases.  2014;232(10):2814-18.
346. Kjeldsen SE, Berge E, Bangalore S, Messerli FH, Mancia G, Holzhauer B, Hua TA, Zappe D, Zanchetti A, Weber MA, Julius S.  No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.  Blood Pressure. 2016;25(2):83-92.
347. Aksnes TA, Kjeldsen SE, Rostrup M, Holzhauer B, Hua TA, Julius S. Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The VALUE trial. Blood Pressure 2016; in press.
348. Palatini P, Rosei EA, Casiglia E, Chalmers J, Ferrari R, Grassi G, Inoue T, Jelakovic B, Jensen MT, Julius S, Kjeldsen SE, Mancia G, Parati G, Pauletto P, Stella A, Zanchetti A.  Management of the hypertensive patient with elevated heart rate: statement of the second consensus conference endorsed by the European Society of Hypertension.  J Hypertens 2016 Mar 15. Epub ahead of print

Books Written and Edited

1.         Mudrost Tijela (Wisdom of our body) Epoha, Zagreb 1960

Slovenian translation Cankarjeva  Zalozba, Ljubljana 1962

2.         Na Zivcanoj Bazi (On a nervous basis) Epoha Zagreb, 1960

Slovenian translation Cankarjeva  Zalozba, Ljubljana 1960

Hungarian translation Forum, Novi Sad 1962

3.         Julius S, Esler MD, ed. The Nervous System in Arterial Hypertension.  Springfield, IL Charles C Thomas, 1976

4          Neither Red Nor Dead  Medvista,  AnnArbor, 2003

Croatian translation Durieux, Zagreb 2005

5.         Adventures In Hypertension  Medvista,  AnnArbor2008

Croatian translation A.G. Matos, Zagreb 2011

6.         Julius S, Palatini P.  Resting heart rate as a cardiovascular risk factor. CESI srl, Rome 2015

 

Chapters in Books (Peer-reviewed):

1.         Julius S:  “Effect of autonomic blockade in normal cardiac output type of borderline hypertension”, in: P Milliez and M Safar (eds.), Recent Advances in Hypertension.  Reims, France, Boehringer Ingelheim (2nd ed.), pp. 217-226, 1975.

2.         Esler M, Julius S, Randall O:  “Relationship of volume factors, renin and neurogenic vascular resistance in borderline hypertension”, in: G Rorive and H Van Cauwenberge (eds.), The Arterial Hypertensive Disease – A Symposium.  Paris, P Masson, pp. 231-249, 1976.

3.         Julius S:  “Neurogenic component in borderline hypertension” in: S Julius and M Esler (eds.), The Nervous System in Arterial Hypertension.  Springfield, Illinois, Charles C. Thomas, pp. 301-330, 1976.

4.         Esler MD, Julius S, Randall O, Kashima T:  “Renin and indices of neurogenic activity in borderline hypertension”, in: S Julius and M Esler (eds.), The Nervous System in Arterial Hypertension.  Springfield, Illinois, Charles C. Thomas, pp. 331-354, 1976.

5.         Julius S, Esler M, Hansson L, Zweifler AJ:  “Dissociation of the renin lowering and antihypertensive actions of propranolol”, in: G Hitzenberger (volume ed.) Advances in Clinical Pharmacology.  Beta-Blocker in der Hypertonie-Behandlung (Vol. 11).  Munchen-Wien-Baltimore, Urban and Schwarzenberg, pp. 33-41, 1976.

6.         Julius S:  “Classification of hypertension”, in: J Genest, E Koiw and O Kuchel (eds.), Hypertension.  New York, McGraw-Hill, pp. 9-12, 1977.

7.         Julius S:  “Borderline hypertension: epidemiological and clinical implications”, in: J Genest, E Koiw and O Kuchel (eds.), Hypertension.  New York, McGraw-Hill, pp. 630-640, 1977.

8.         Julius S, Esler M:  “Patterns of neurogenic involvement in borderline and essential hypertension”, in: W DeJong, AP Provoost and AP Shapiro (eds.), Progress in Brain Research, Hypertension and Brain Mechanisms.  Amsterdam, Elsevier Series Vol. 47, pp. 251-262, 1977.

9.         Julius S:  “Borderline hypertension: significance and management”, in: G Onesti and AN Brest (eds.), Cardiovascular clinics 9/1, Hypertension: Mechanisms, Diagnosis and Treatment.  Philadelphia, FA Davis Co., pp. 31-41, 1978.

10.       Julius S and Schork MA:  “Predictors of hypertension”, in: HM Perry, Jr. and WM Smith (eds.), Mild Hypertension: To Treat or Not to Treat .  Annals of the New York Academy of Sciences, New York Academy of Sciences Vol. 304, pp. 38-52, 1978.

11.       Julius S:  “Borderline hypertension: clinical and pathophysiologic significance”, in: H von P Frick, G-A von Harnack, GA Martini, A Prader, R Schoen and HP Wolff (eds.), Advances in Internal Medicine and Pediatrics.  Heidelberg, Springer-Verlag, Vol. 41, pp. 52-84, 1978.

12.       Kiowski W, Rojas-Vigo AE, Julius S:  “Hemodynamic studies of ticrynafen in hypertension”, in: NM Kaplan (ed.), A New Class of Diuretics with Uricosuric Activity, A symposium developed from a clinical seminar.  Postgraduate Medicine Communications, pp. 25-35, 1979.

13.       Julius S, Zweifler AJ, Nicholls MG:  “Beta-adrenergic blocking agents in the treatment of hypertension”, in: E Rapaport (ed.), Cardiology Update – Reviews for Physicians.  New York, Elsevier North Holland, pp. 329-346, 1979.

14.       Julius S:  “Hemodynamic evidence for central nervous involvement in mild hypertension”, in: Y Yamori, W Lovenberg and ED Freis (eds.), Perspectives in Cardiovascular Research. Prophylactic Approach to Hypertensive Diseases.  New York, Raven Press, pp. 309-314, 1979.

15.       Julius S, Quadir H, Gajendragadkar S:  “Hyperkinetic state: A precursor of hypertension?  A longitudinal study of borderline hypertension”, in: F Gross and T Strasser (eds.), Mild Hypertension: Natural History and Management.  London, Pittman Medical Publishing Co., Ltd., pp. 116-126, 1979.

16.       Julius S:  “Importancia clinica de la hipertension arterial fronteriza”, in: AG Caamano and LA Diaz-Barreiro (eds.), Hipertension Arterial, Mexico, Ediciones Medicas Actualizadas, S.A., pp. 309-316, 1980.

17.       Julius S:  “The psychophysiology of borderline hypertension”, in: H Weiner, MA Hofer and AJ Stunkard (eds.), Brain, Behavior, and Bodily Disease.  New York, Raven Press, pp. 293-303, 1981.

18.       Julius S, Simon G:  “Mechanisms of antihypertensive action of beta-blocking agents.  Lessons from a timolol trial”, in: Proceedings of the Timolol Intercontinental Symposium.  New York, Biomedical Information Corp., pp. 131-143, 1981.

19.       Julius S:  “Hypertension: clinical review”, in: DL Parron, F Solomon and RJ Haggerty (eds.), Proceedings of Pharmacological and Psychosocial Treatment Approaches: Issues and Interrelationships.  Washington, D.C., National Academy Press, 1981.

20.       Julius S:  “Borderline hypertension”, in: H Brunner and H Gavras (eds.), Clinical Hypertension and Hypotension.  New York, Marcel Dekker, Inc., pp. 313-325, 1982.

21.       Julius S:  “Psychophysiologic evidence for the role of the nervous system in hypertension”, in: A Amery, R Fagard, P Lijnen and J Staessen (eds.), Hypertensive Cardiovascular Disease: Pathophysiology and Treatment.  Boston, Martinus Nijhoff Publishers, pp. 217-230, 1982.

22.       Julius S:  “Historia natural de la hipertension arterial fronteriza sus repercusiones en la practica clinica”, in: AG Caamano and LA Diaz-Barreiro (eds.), Hipertension Arterial.  Mexico, Ediciones Medicas Actualizadas, S.A., pp. 183-189, 1982.

23.       Julius S, Hansson L:  “Classification of hypertension”, in: J Genest, O Kuchel, P Hamet, M Cantin (eds.), Hypertension:  Physiopathology and Treatment (2^nd ed.).  New York, McGraw-Hill, pp. 679-682, 1983.

24.       Julius S, Hansson L:  “Borderline hypertension: epidemiologic and clinical implications”, in: J Genest, O Kuchel, P Hamet, M Cantin (eds.), Hypertension: Physiopathology and Treatment (2^nd ed.). New York, McGraw-Hill, pp. 753-764, 1983.

25.       Egan B, Julius S: “Borderline hypertension”, in: HR Black (ed.), Symposium on Hypertension in Office Practice, Primary Care, pp. 99-113, 1983.

26.       Julius S, Cottier C:  “Behavior and hypertension”, in: TM Dembroski, TH Schmidt, G Blumchen (eds.), Biobehavioral Bases of Coronary Heart Disease.  Karger Biobehavioral Medicine Series, Vol. 2, Basel, S. Karger AG, pp. 271-289, 1983.

27.       Julius S, Weder A, Egan BM:  “Pathophysiology of early hypertension: implication for epidemiologic research”, in: F Gross, T Strasser (eds.), Mild Hypertension: Recent Advances.  New York, Raven Press, pp. 219-236, 1983.

28.       Julius S:  “Antihypertensive treatment in borderline hypertension”, in: HM Perry (ed.), Lifelong Management of Hypertension.  Boston, Martinus Nijhoff, pp. 46-56, 1983.

29.       Julius S:  “Hypertension”, in: S Julius (ed.), A Comprehensive Guide to the Therapeutic Use of Trasicor (Pharmanual).  Basel, S. Karger AG, pp. 1-7, 1984.

30.       Julius S:  “Stress and psychosomatic cardiovascular disorders”, in: S Julius (ed.), A Comprehensive Guide to the Therapeutic Use of Trasicor (Pharmanual).  Basel, S. Karger AG, pp. 17-23, 1984.

31.       Julius S:  “Type A behavior”, in: S Julius (ed.), A Comprehensive Guide to the Therapeutic Use of Trasicor (Pharmanual).  Basel, S. Karger AG, pp. 24-29, 1984.

32.       Julius S:  “Psychosomatic cardiovascular disorders and coronary-prone behavior”, in: S Julius (ed.), A Comprehensive Guide to the Therapeutic Use of Trasicor (Pharmanual).  Basel, S. Karger AG, pp. 50-56, 1984.

33.       Julius S, Fitzpatrick MA, Egan B, Schneider R:  “Neural mechanisms in clinical hypertension”, in: GP Guthrie, Jr. and TA Kotchen (eds.), Hypertension and the Brain.  New York, Futura Publications, pp. 305-318, 1984.

34.       Fitzpatrick MA, Julius S:  “The role of the nervous system in the etiology and evolution of essential hypertension”, in: GP Guthrie, Jr. and TA Kotchen (eds.), Hypertension and the Brain.  New York, Futura Publications, pp. 319-325, 1984.

35.       Julius S, Ibsen H, Colfer HT.  “Hemodynamic and pharmacologic correlates of plasma norepinephrine in hypertension”, in: MG Ziegler and CR Lake (eds.), Norepinephrine-Vol. 2: Frontiers of Clinical Neuroscience.  Baltimore, Williams & Wilkins, pp. 401-409, 1984.

36.       Zweifler AJ, Julius S:  “Medical treatment of renovascular hypertension”, in: JC Stanley, CB Ernst, and WJ Fry (eds.), Renovascular Hypertension.  Philadelphia, W. B. Saunders Co., pp. 231-245, 1984.

37a.     Julius S, Fitzpatrick MA:  “Neurogenic hypertension”, in: TM Bayless, MC Brain and RM Cherniack (eds.), Current Therapy in Internal Medicine.  Philadelphia, BC Decker, Inc., pp. 1231-1234, 1984.

37b.     Julius S, Fitzpatrick MA:  “Neurogenic hypertension”, in:  RJ Glassock, Series Editor (ed.), Current Therapy in Nephrology and Hypertension.  Philadelphia, B. C. Decker, Inc., pp. 340-344, 1984.

38.       Julius S.  “Controversies in the research on hemodynamic mechanisms in the development of hypertension”, in: MP Sambhi (ed.), Fundamental Fault in Hypertension, Developments in Cardiovascular Medicine.  Boston, Martinus Nijhoff Publishers, pp. 263-275, 1984.

39.       Julius S:  “Implications for hypertension”, in: SM Weiss, KA Matthews, T Detre and JA Graeff (eds.), Stress, Reactivity, and Cardiovascular Disease.  Proceedings of the Working Conference.  Washington, USPHS, National Institutes of Health (Publication No. 84-2698), pp. 63-71, 1984.

40.       Julius S, Schneider R, Egan B:  “Suppressed anger in hypertension: facts and problems”, in: MA Chesney and R Rosenman (eds.), Anger and Hostility in Behavioral and Cardiovascular Disorders.  Hemisphere Publishing Corp, Washington, D.C., pp. 127-137, 1985.

41.       Schneider R, Julius S, Moss G:  “Physiological correlates of the type A coronary-prone behaviour pattern and the influence of metoprolol ( Lopressor): a preliminary report”, in: A Zanchetti and P Turner (eds.), Towards Preventive Treatment of Coronary-Prone Behaviour.  Hans Huber Publishers, Berne, Switzerland, pp. 42-48, 1985.

42.       Julius S, Weder AB, Hinderliter AL:  “Does behaviorally induced blood pressure variability lead to hypertension?” in: KA Matthews (ed.), Stress, Reactivity, and Cardiovascular Disease.  New York, John Wiley & Sons, Inc., pp. 71-82, 1986.

43.       Julius S, Egan B, Hinderliter A:  “Assessment of autonomic function in essential hypertension”, in:  RCA Frederickson, HC Hendrie, JN Hingtgen and MH Aprison (eds.), Neuroregulation of Autonomic, Endocrine, and Immune Systems.  Boston, Martinus-Nijhoff, pp. 183-198, 1986.

44.       Julius S, Egan B:  “Hemodynamics of hypertension”, in: A Zanchetti, RC Tarazi (eds.), Handbook of Hypertension, Vol. 7: Pathophysiology of Hypertension – Cardiovascular Aspects.  Amsterdam, Elsevier, pp. 153-178, 1986.

45.       Egan BM, Julius S:  “Cardiac reflexes and blood pressure elevation”, in: FH Messerli (ed.), The Heart and Hypertension.  New York, Cahners Publishing Company, pp. 11-19, 1987.

46.       Julius S:  “Hemodynamic, pharmacologic and epidemiologic evidence for behavioral factors in human hypertension”, in: S Julius and DR Bassett (eds.), Handbook of Hypertension, Vol. 9: Behavioral Factors in Hypertension.  Amsterdam, Elsevier Science Publishers, pp. 59-74, 1987.

47.       Weder AB, Julius S:  “Behavior, blood pressure variability and hypertension:  A research agenda”, in: S Julius and DR Bassett (eds.), Handbook of Hypertension, Vol. 9: Behavioral Factors in Hypertension.  Amsterdam, Elsevier Science Publishers, pp. 312-31, 1987.

48.       Julius S:  “Pathophysiology of hypertension – hemodynamic aspects”, in: L. Hansson (ed.), The 1987 Hypertension Annual.  London, Gower Academic Journals, pp. 37-56, 1987.

49.       Julius S:  “Borderline hypertension”, in: Hurst et al (eds.), Medicine for the Practicing Physician.  Butterworth Publishers, Massachusetts, pp. 889-891, 1988.

50.       Julius S:  “Borderline hypertension”, in: Hurst, et al (eds.), Criteria for Diagnosis.  Butterworth Publishers, Massachusetts, p. 304, 1989.

51.       Julius S:  “Hemodynamic assessment and pharmacologic probes as tools to analyze cardiovascular reactivity”, in: N Schneiderman, SM Weiss and P Kaufmann (eds.), Handbook of Research Methods in Cardiovascular Behavioral Medicine.  New York, Plenum Press, pp. 411-416, 1989.

52.       Egan B, Julius S:  “The hemodynamics of borderline hypertension”, in: ME Safar and F Fouad-Tarazi (eds.), The Heart in Hypertension.  Dordrecht, Kluwer Academic Publishers, pp. 47-66, 1989.

53.       Julius S, Petrin J:  “Autonomic nervous and behavioral factors in hypertension”, in: JH Laragh and BM Brenner (eds.), Hypertension: Pathophysiology, Diagnosis, and Management.  New York, Raven Press, pp. 2083-2090, 1990.

54.       Johnson EH, Julius S:  “Is there a hypertensive coronary-prone personality?”, in: F Buhler and J Laragh (eds.), Handbook of Hypertension, Vol. 13: The Management of Hypertension.  Amsterdam, Elsevier Science Publishers, pp. 33-41, 1990.

55.       Cox JP, Julius S, O’Malley K, O’Brien E: “Self-measurement of blood pressure”, in Handbook of Hypertension.  Amsterdam, Elsevier Science Publishers, pp. 112-125, 1991.

56.       Julius S:  “Relationship between the sympathetic tone and cardiovascular responsiveness in the course of hypertension”, in: EH Johnson, WD Gentry and S Julius (eds.), Personality, Elevated Blood Pressure, and Essential Hypertension.  New York, Hemisphere Publishing Corporation, pp. 219-230, 1992.

57.       Julius S:  “Borderline hypertension: Management”, in: JL Izzo, Jr and HR Black (eds.), American Heart Association Hypertension Primer, Chapter E20, Dallas, American Heart Association, pp. 333-336, 1993.

58.       Weder A, Julius S:  “Pathophysiology of hypertension and treatment” in: BN Singh, VJ Dzau, PM Vanhoutte and RL Woosley (eds.), Cardiovascular Pharmacology and Therapeutics, Chapter 57, New York, Churchill Livingstone Inc., pp. 861-883, 1994.

59.       Julius S:  “Evolution of hemodynamic and neuroendocrine changes in the course of hypertension” in FH Messerli (ed.), The ABC’s of Antihypertensive Therapy, Chapter 3, New York, Raven Press, pp. 17-26, 1994.

60.       Amerena J, Julius S: “Role of the nervous system in human hypertension,” in NK Hollenberg (ed.) Atlas of Heart Diseases.  Hypertension: Mechanisms and Therapy, Chapter 2, Philadelphia, Current Medicine, pp. 2.1-2.23 (Vol 1), 1994.

61.       Julius S:  “The changing relationship between autonomic control and haemodynamics of hypertension”, in: JD Swales (ed.), Textbook of Hypertension.  Oxford, Blackwell Scientific Publications, pp. 77-84, 1994.

62.       Julius S, Amerena J, Smith S, Petrin J:  “Autonomic nervous and behavioral factors in hypertension”, in: JH Laragh and BM Brenner (eds.), Hypertension:  Pathophysiology, Diagnosis, and Management.  New York, Raven Press, pp. 2557-2569 (2^nd ed), 1995.

63.       Amerena J, Julius S: “Role of the nervous system in human hypertension”, in NK Hollenberg (eds.) Atlas of Heart Diseases.  Hypertension: Mechanisms and Therapy, Chapter 2, Philadelphia, Current Medicine, 2.1-2.24 (2^nd ed), 1998.

64.       Julius S:  “Management of borderline hypertension”, in: JL Izzo, Jr and HR Black (eds.), American Heart Association Hypertension Primer, Chapter 150, Dallas, American Heart Association, pp. 433-436 (2^nd ed), 1999.

65.       Amerena J, Julius S:  “Neurogenic hypertension”, in RJ Johnson and J Freehally (eds.), Comprehensive Clinical Nephrology, Chapter 43, London, Harcourt Publishers Ltd., pp. 43.1-43.6, 2000.

66.       Julius S, Nesbitt S:  “Evolution of hemodynamic and neuroendocrine changes in the course of hypertension”, in FH Messerli (ed.), The ABC’s of Antihypertensive Therapy, Chapter 3, New York, Authors’ Publishing House, pp. 13-23 (2^nd ed), 2000.

67.       Julius S: “Neuroendocrine factors.  Role of sympathetic nervous and renin angiotensin systems”, in MA Weber (ed), Hypertension Medicine, Chapter 7, Totowa, NJ, Humana Press Inc., pp. 89-97, 2001.

68.       Amerena J, Julius S: “Role of the nervous system in human hypertension,” in NK Hollenberg, E Braunwald (eds.) Atlas of Heart Diseases.  Hypertension: Mechanisms and Therapy, Chapter 2, Philadelphia, Current Medicine, Inc., pp. 34-58 (3^rd ed), 2001.

69.       Palatini P, Julius S: “Blood pressure and atherosclerotic risk factors,” in A Zanchetti (ed), Hypertension: Clinical Medicine Series, Chapter 1, England, McGraw-Hill International (UK) Ltd., pp. 3-11, 2001.

70.       Kjeldsen SE, Julius S, Weber MA, Stolt P: “Main results from VALUE,” in S Oparil, MA Weber (eds), Hypertension, Companion to Brenner & Rector’s The Kidney, pp. 376-380, 2005.

71.       Kjeldsen SE, Julius S, Pedersen O, Stöset O: “Recent hypertension trials,” in H Brunner (ed), The Year in Hypertension Volume 6, Chapter 1, Oxford, UK, Clinical Publishing, pp. 4-14, 2006.

72.       Julius S: “Heart Rate and Hypertension,” in: K Fox (ed), Slow the Heart, Beat the Disease.  Amsterdam, Elsevier Science Publishers, pp. 26-36, 2011.

73.       Julius S, Feldstein CA: “Prehypertension: definitions, clinical significance and therapeutic approaches –to treat or not to treat?” in AE Berbari, G Mancia, (eds) Special Issues in Hypertension.  Milan, Springer Verlag Italia Srl, 3-12, 2012.

 

Books or Journals Edited

1.         Julius S, Esler MD:  The Nervous System in Arterial Hypertension, Springfield, Illinois, Charles C. Thomas, p. 476, 1976.

2.         Hansson L, Julius S, Richardson PJ:  Proceedings of the Timolol Intercontinental Symposium, (Stockholm, Sweden, October 27-28, 1979), New York, Biomedical Information Corporation, p. 456, 1981.

3.         Julius S (by invitation):  A Comprehensive Guide to the Therapeutic Use of Trasicor (Pharmanual).  Basel, S. Karger AG, p. 115, 1984.

4.         Julius S, Bassett DR:  Handbook of Hypertension, Vol. 9:  Behavioral Factors in Hypertension, Amsterdam, Elsevier Publishers, p. 352 , 1987.

5.         Julius S, Chobanian A.  Hypertension:  A view beyond numbers.  American Heart Journal 116, No. 1, Part 2, 1988.

6.         Johnson EH, Gentry WD and Julius S:  Personality, elevated blood pressure, and essential hypertension; Health Psychology and Behavioral Medicine, Hemisphere Publishing, 1992.

7.        Zanchetti A, Hansson L, Rodicio JL, Julius S:  Hypertension.  McGraw-Hill International (UK) Ltd., London, 2001.

8.         van Zwieten PA, Julius S, AT₁ blockers: are there alternative pathways reducing cardiovascular risk?  Satellite symposium to ESH, Journal of Hypertension, 2001.

9.         Mancia G, Chalmers J, Julius S, Saruta T, Weber M, Ferrari A, Wilkinson I:  Manual of Hypertension.  Churchill Livingstone, Harcourt Publishers Limited, London, 2002.